First Line Study of Irinotecan, Capecitabine and Oxaliplatin in Metastatic Gastric or Gastroesophageal Cancer.

NCT01129310 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Gastrointestinal Neoplasm
Gastric Adenocarcinoma

Interventions

DRUG: Irinotecan-Capecitabine-Oxaliplatin

Sponsor

AHS Cancer Control Alberta

Collaborators

[object Object]